We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Prognostic Biomarker Detects Acute Kidney Injury

By LabMedica International staff writers
Posted on 08 Aug 2011
A renal injury biomarker in urine or blood detects early subclinical acute kidney injury (AKI) and its adverse outcomes in critically ill patients. More...


Early testing for the biomarker, neutrophil gelatinase-associated lipocalin (NGAL) may therefore allow earlier conventional medical interventions or introduction of novel therapies to improve the prognosis of AKI.

In a retrospective study, involving 13 international medical organizations, data from 2,322 critically ill adult and pediatric patients was pooled. These same patients did not have diagnostic increases in serum creatinine, which is considered the current gold standard for detecting AKI. The critically ill patients whose data was analyzed primarily had Type 1 cardiorenal syndrome, a common condition in which heart dysfunction causes kidney injury.

The scientists recorded that 40% of the patients showed unexpected early increases in urine or blood NGAL levels, but no increases in serum creatinine. These early increases in NGAL concentration had a much greater risk of adverse medical outcomes than patients who tested negative for NGAL. NGAL positive patients were 16 times more likely to need dialysis, three times more likely to die during hospitalization, and on average, they spent three extra days in intensive care and eight extra days in the hospital.

Prasad Devarajan, MD, is one of the lead authors of the study, and a departmental director at Cincinnati Children's Hospital Medical Center, (Cincinnati, OH, USA). He said, "This study describes a new biomarker (NGAL) that completely outperforms the current serum creatinine-based criteria for the early detection of AKI and its devastating clinical outcomes. We concluded that a substantial numbers of patients might reasonably be classified as having subclinical AKI, even though they do not fulfill current creatinine-based criteria for AKI." The researchers now plan to pursue a prospective multicenter study to further verify the effectiveness of the NGAL test as a prognostic biomarker in a large population of patients in critical care settings. The study was published on April 26, 2011, in the Journal of the American College of Cardiology (JACC).

Related Links:

Cincinnati Children's Hospital Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.